Evidence map›Paper›PMID 32864010›Full record

ArticleArchives of medical science : AMS2020

Up-regulation of

Baihetiya Azhati, Naibijiang Maolakuerban, Tao Ma, Xiaodong Li, Mulati Rexiati

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of medical science : AMS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. The Clinical Spectrum and Disease Course of DRAM2 Retinopathy.International journal of molecular sciences · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Baihetiya AzhatiDepartment of Urology, First Affiliated Hospital of Xinjiang Medical University, Urumchi, Xinjiang, China.
Naibijiang MaolakuerbanDepartment of Urology, First Affiliated Hospital of Xinjiang Medical University, Urumchi, Xinjiang, China.
Tao MaDepartment of Urology, First Affiliated Hospital of Xinjiang Medical University, Urumchi, Xinjiang, China.
Xiaodong LiDepartment of Urology, First Affiliated Hospital of Xinjiang Medical University, Urumchi, Xinjiang, China.
Mulati RexiatiDepartment of Urology, First Affiliated Hospital of Xinjiang Medical University, Urumchi, Xinjiang, China.
Xinjiang Medical University · CNFirst Affiliated Hospital of Xinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBladder transitional cell carcinoma (BTCC) is one of the most prevalent human malignant diseases. Gemcitabine is commonly applied in the treatment of BTCC while acquired gemcitabine resistance has caused a severe impediment to recovery. This study aimed to investigate the function of MATERIAL AND

methodsGSE77883 was introduced to screen out the differentially expressed autophagy-related genes in T24 cells and gemcitabine-resistant T24-GEM cells. After establishing T24-GEM cells ourselves, aberrant expression of

results

conclusionsOur data suggested that downregulation of

Indexed as

autophagybladder cancerDRAM2gemcitabine

Identifiers

PMID32864010
PMCPMC7444702
OpenAlexW3034178517

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.